The specter of generic competition has long loomed over copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of connected pharmaceutical portfolios. While initial times saw impressive gains, the exclusivity end has allowed the door for discounted substitutes, potentially reducing profitability and creating a significant